GLP-1 Drugs Linked to 30 Percent Lower Breast Cancer Risk in New Study

New research presented at the American Society of Clinical Oncology''s 2026 annual meeting found that GLP-1 receptor agonists, the class of drugs that includes Ozempic and Wegovy, are linked to a 30 percent lower risk of breast cancer in women.

The study examined data from thousands of women who used GLP-1 medications for weight management or diabetes treatment. Researchers found that the cancer risk reduction held across multiple breast cancer subtypes, though the mechanism behind the association is not yet fully understood.

Scientists believe the drugs may reduce cancer risk through several pathways, including lowering insulin levels, reducing inflammation, and promoting weight loss, all of which are known to influence cancer development. The findings were reported by Science Daily and covered by multiple health outlets this week.

The results add to a rapidly expanding list of potential benefits from GLP-1 drugs beyond their original purpose. Earlier research has linked the medications to lower rates of heart disease, kidney disease, and certain neurological conditions.

Oncology nurses and researchers at ASCO noted that the findings are promising but require further study before they can be used to guide clinical decisions. The research was observational, meaning it identified an association rather than proving the drugs directly cause the cancer risk reduction.

For women already taking GLP-1 medications for weight or blood sugar management, the findings offer an additional potential benefit. Doctors caution, however, that the drugs are not without side effects, including nausea, muscle loss, and reduced daily movement, which can offset some health gains if patients do not maintain physical activity.

The study is expected to prompt further clinical trials designed to test whether GLP-1 drugs can be used specifically for cancer prevention.